MX2022010537A - Anticuerpos contra el coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2) y metodos de uso de los mismos. - Google Patents

Anticuerpos contra el coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2) y metodos de uso de los mismos.

Info

Publication number
MX2022010537A
MX2022010537A MX2022010537A MX2022010537A MX2022010537A MX 2022010537 A MX2022010537 A MX 2022010537A MX 2022010537 A MX2022010537 A MX 2022010537A MX 2022010537 A MX2022010537 A MX 2022010537A MX 2022010537 A MX2022010537 A MX 2022010537A
Authority
MX
Mexico
Prior art keywords
cov
methods
antigen
sars
same
Prior art date
Application number
MX2022010537A
Other languages
English (en)
Inventor
Katja Fink
Davide Corti
Elisabetta Cameroni
Martina Beltramello
Dora Pinto
Gyorgy Snell
Florian A Lempp
Amalio Telenti
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of MX2022010537A publication Critical patent/MX2022010537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que pueden unirse a un antígeno del SARS-CoV-2 y, en ciertas modalidades, son capaces de neutralizar una infección por SARS-CoV-2. También se proporcionan polinucleótidos que codifican para un anticuerpo o fragmento de unión a antígeno, vectores y células hospederas que comprenden un polinucleótido, composiciones farmacéuticas y métodos para usar los anticuerpos, fragmentos de unión a antígeno, polinucleótidos, vectores, células hospederas y composiciones descritos en la presente para tratar o diagnosticar una infección por SARS-CoV-2.
MX2022010537A 2020-02-26 2021-02-25 Anticuerpos contra el coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2) y metodos de uso de los mismos. MX2022010537A (es)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US202062981984P 2020-02-26 2020-02-26
US202062982661P 2020-02-27 2020-02-27
US202062987298P 2020-03-09 2020-03-09
US202062989522P 2020-03-13 2020-03-13
US202062990369P 2020-03-16 2020-03-16
US202062992082P 2020-03-19 2020-03-19
US202062994235P 2020-03-24 2020-03-24
US202063001204P 2020-03-27 2020-03-27
US202063003214P 2020-03-31 2020-03-31
US202063005206P 2020-04-03 2020-04-03
US202063010589P 2020-04-15 2020-04-15
US202063011971P 2020-04-17 2020-04-17
US202063014024P 2020-04-22 2020-04-22
US202063023788P 2020-05-12 2020-05-12
US202063025133P 2020-05-14 2020-05-14
US202063039813P 2020-06-16 2020-06-16
US202063043653P 2020-06-24 2020-06-24
US202063050331P 2020-07-10 2020-07-10
US202063052810P 2020-07-16 2020-07-16
PCT/US2021/019531 WO2021173753A1 (en) 2020-02-26 2021-02-25 Antibodies against sars-cov-2 and methods of using the same

Publications (1)

Publication Number Publication Date
MX2022010537A true MX2022010537A (es) 2022-09-21

Family

ID=74758682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010537A MX2022010537A (es) 2020-02-26 2021-02-25 Anticuerpos contra el coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2) y metodos de uso de los mismos.

Country Status (26)

Country Link
US (3) US11168128B2 (es)
EP (2) EP4245373A3 (es)
JP (2) JP7275405B2 (es)
KR (1) KR20220164465A (es)
AU (2) AU2021227687B2 (es)
BR (1) BR112022017048A2 (es)
CA (1) CA3158752C (es)
CL (1) CL2022002335A1 (es)
CO (1) CO2022013525A2 (es)
DK (1) DK3872091T5 (es)
ES (1) ES2954629T3 (es)
FI (1) FI3872091T3 (es)
HR (1) HRP20231031T1 (es)
HU (1) HUE062777T2 (es)
IL (1) IL295801A (es)
LT (1) LT3872091T (es)
MA (1) MA56074B1 (es)
MX (1) MX2022010537A (es)
PL (1) PL3872091T3 (es)
PT (1) PT3872091T (es)
RS (1) RS64645B1 (es)
SG (1) SG11202110145SA (es)
SI (1) SI3872091T1 (es)
SM (1) SMT202300397T1 (es)
TW (1) TWI859420B (es)
WO (1) WO2021173753A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
AU2020356407A1 (en) * 2019-09-25 2022-04-07 Universität Stuttgart Binding modules comprising modified EHD2 domains
FI4045533T3 (fi) * 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
MY197648A (en) 2020-04-02 2023-06-30 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
TW202204397A (zh) 2020-04-10 2022-02-01 美商亞得捷歐治療公司 對冠狀病毒s蛋白質具特異性之化合物及其用途
KR20230019166A (ko) 2020-06-03 2023-02-07 리제너론 파아마슈티컬스, 인크. 항-SARS-CoV-2 스파이크 당단백질 항체를 이용한 SARS-CoV-2 감염 및 COVID-19 치료 또는 예방 방법
AU2021288203A1 (en) * 2020-06-12 2023-01-19 Vir Biotechnology, Inc. Antibody therapies for SARS-CoV-2 infection
AU2021305067A1 (en) 2020-07-06 2023-02-09 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting SARS-CoV-2
CA3183367A1 (en) * 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CN116528897A (zh) 2020-08-26 2023-08-01 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
WO2022054068A1 (en) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Antibodies for the prevention, treatment and detection of coronavirus infection
US20220091132A1 (en) * 2020-09-22 2022-03-24 Becton, Dickinson And Company Cell-based assay for detection of antibodies in a sample
EP4228697A4 (en) 2020-10-16 2025-01-01 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
US12109237B2 (en) * 2020-12-15 2024-10-08 Rutgers, The State University Of New Jersey S309 chimeric antigen receptors and methods of use
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023001736A1 (en) 2021-07-19 2023-01-26 Universität Für Bodenkultur Wien ENGINEERED ANTI-SARS COV-2 IgG3 ANTIBODIES
WO2023034871A1 (en) * 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
US20240400652A1 (en) * 2021-09-01 2024-12-05 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023039442A1 (en) * 2021-09-08 2023-03-16 Vir Biotechnology, Inc. Broadly neutralizing antibody combination therapies for sars-cov-2 infection
WO2023039540A2 (en) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
WO2023044397A1 (en) * 2021-09-15 2023-03-23 The Board Of The Trustees Of The University Of Illinois Engineered receptors and monoclonal antibodies for coronaviruses and uses thereof
WO2023046057A1 (zh) * 2021-09-24 2023-03-30 南京金斯瑞生物科技有限公司 抗SARS-CoV-2 L452R刺突蛋白的单克隆抗体及其应用
WO2023056522A1 (en) * 2021-10-07 2023-04-13 Seqirus Pty Ltd Anti-sars-cov-2 antibodies and uses thereof ii
WO2023086827A1 (en) * 2021-11-09 2023-05-19 Rhode Island Hospital Predicting covid-19 antibodies among survivors with deep rna sequencing
EP4433613A1 (en) 2021-11-15 2024-09-25 VIR Biotechnology, Inc. Virological and molecular surrogates of response to sars-cov-2 neutralizing antibody sotrovimab
WO2023094980A1 (en) * 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
CN114107223B (zh) * 2021-11-25 2024-03-26 湖北省疾病预防控制中心（湖北省预防医学科学院） 利用TPCK胰酶提高SARS-CoV-2病毒细胞培养滴度的方法
WO2023122211A2 (en) * 2021-12-21 2023-06-29 Duke University Coronavirus antibodies and uses thereof
EP4460516A2 (en) * 2022-01-03 2024-11-13 Twist Bioscience Corporation Bispecific sars-cov-2 antibodies and methods of use
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン
CN116444656B (zh) * 2022-01-10 2023-09-22 东莞市朋志生物科技有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法
TWI868567B (zh) * 2022-01-26 2025-01-01 中央研究院 冠狀病毒之特異性抗體及其用途
WO2023150307A2 (en) * 2022-02-03 2023-08-10 Abpro Corporation Compositions and methods against a virus
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023201256A1 (en) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
CA3256034A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
CA3256035A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
EP4519310A1 (en) 2022-05-06 2025-03-12 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
WO2023224714A1 (en) * 2022-05-16 2023-11-23 Lawrence Livermore National Security, Llc Repaired therapeutic and prophylactic antibodies against sars-cov-2 variants
KR20240008997A (ko) * 2022-07-12 2024-01-22 (재) 스크립스코리아항체연구원 사스-코로나 바이러스 2 중화 항체
WO2024058987A2 (en) * 2022-09-14 2024-03-21 Merck Sharp & Dohme Llc Polypeptides effective against multiple coronaviruses
AU2023375894A1 (en) 2022-11-13 2025-05-22 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
WO2024112818A1 (en) * 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004024750A2 (en) 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
CA2521856A1 (en) 2003-04-08 2004-10-21 Coronovative B.V. Severe acute respiratory syndrome (sars) causing coronavirus
EP1644414B1 (en) 2003-07-22 2015-01-14 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
US7396914B2 (en) 2003-08-04 2008-07-08 University Of Massachusetts SARS nucleic acids, proteins, antibodies, and uses thereof
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
US7553944B2 (en) 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2652728A1 (en) 2006-05-19 2008-05-22 Amgen Inc. Antibodies to sars coronavirus
CN101522717A (zh) 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
CA2678628A1 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
WO2009128963A2 (en) 2008-01-17 2009-10-22 Humab, Llc Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2009097133A2 (en) 2008-01-30 2009-08-06 Monsanto Technology, Llc Transgenic plants with enhanced agronomic traits
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
LT2504364T (lt) 2009-11-24 2017-11-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
KR101299753B1 (ko) 2010-11-19 2013-08-23 주식회사 단바이오텍 소 코로나바이러스 항원 결정기를 포함하는 스파이크 재조합 단백질 및 이에 대한 항체
HUE041900T2 (hu) 2012-01-20 2019-06-28 Genzyme Corp Anti-CXCR3 ellenanyagok
AR090244A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
BR112014028764A2 (pt) 2012-05-18 2017-06-27 Novozymes As mutante isolado, métodos para a obtenção do mutante isolado e de um lactobacillus transformante, e, lactobacillus transformante.
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
EA201792250A1 (ru) 2015-04-10 2018-05-31 Эмджен Инк. Мутеины интерлейкина-2 для роста регуляторных т-клеток
EP3294328A1 (en) 2015-05-08 2018-03-21 Eureka Therapeutics, Inc. Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
KR102398425B1 (ko) 2016-03-08 2022-05-16 이나뜨 파르마 에스.에이. Siglec 중화 항체
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
RU2019121662A (ru) 2016-12-16 2021-01-18 Мерк Патент Гмбх Способы использования галектин-3-связывающего белка, обнаруживаемого в моче, для мониторинга тяжести и прогрессирования волчаночного нефрита
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
CN110914295B (zh) 2017-06-28 2024-08-09 里珍纳龙药品有限公司 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CA3072267A1 (en) 2017-08-09 2019-02-14 University Of Saskatchewan Her3 binding agents and uses thereof
KR101895228B1 (ko) 2017-08-23 2018-10-30 대한민국 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
CN111133003B (zh) 2017-09-22 2024-01-12 上海药明生物技术有限公司 新型双特异性多肽复合物
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
MY197648A (en) * 2020-04-02 2023-06-30 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021203053A1 (en) * 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
JP2023523549A (ja) * 2020-04-14 2023-06-06 ヴィア・バイオテクノロジー・インコーポレイテッド ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
JP2023525039A (ja) * 2020-05-08 2023-06-14 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体
WO2021247925A1 (en) * 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
AU2021288203A1 (en) * 2020-06-12 2023-01-19 Vir Biotechnology, Inc. Antibody therapies for SARS-CoV-2 infection
CN112062859B (zh) * 2020-07-24 2022-08-09 沣潮医药科技（上海）有限公司 用于病原体清除的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
DK3872091T3 (da) 2023-09-11
KR20220164465A (ko) 2022-12-13
AU2021227687B2 (en) 2023-02-23
EP3872091B1 (en) 2023-06-14
PT3872091T (pt) 2023-09-19
US20210261650A1 (en) 2021-08-26
TWI859420B (zh) 2024-10-21
US11168128B2 (en) 2021-11-09
PL3872091T3 (pl) 2023-12-27
MA56074A (fr) 2022-04-06
JP2023505613A (ja) 2023-02-09
EP3872091A1 (en) 2021-09-01
TW202146442A (zh) 2021-12-16
LT3872091T (lt) 2023-10-10
JP2023009046A (ja) 2023-01-19
SI3872091T1 (sl) 2023-12-29
SMT202300397T1 (it) 2024-01-10
DK3872091T5 (da) 2024-08-12
JP7275405B2 (ja) 2023-05-17
SG11202110145SA (en) 2021-10-28
CL2022002335A1 (es) 2023-07-21
MA56074B1 (fr) 2023-11-30
ES2954629T3 (es) 2023-11-23
IL295801A (en) 2022-10-01
US11479599B2 (en) 2022-10-25
HUE062777T2 (hu) 2023-12-28
HRP20231031T1 (hr) 2023-12-22
FI3872091T3 (fi) 2023-08-31
AU2023203201A1 (en) 2023-06-15
WO2021173753A1 (en) 2021-09-02
BR112022017048A2 (pt) 2022-11-16
RS64645B1 (sr) 2023-10-31
US20230331821A1 (en) 2023-10-19
CO2022013525A2 (es) 2022-12-20
EP4245373A3 (en) 2023-12-20
US20210371504A1 (en) 2021-12-02
CA3158752C (en) 2023-08-08
EP4245373A2 (en) 2023-09-20
AU2021227687A1 (en) 2022-10-20
CA3158752A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
MX2022010537A (es) Anticuerpos contra el coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2) y metodos de uso de los mismos.
CO2022017670A2 (es) Anticuerpos contra sars-cov-2
BR112022015374A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
CO2021006248A2 (es) Anticuerpos anti-nkg2a y usos de los mismos
DOP2021000026A (es) Anticuerpos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
PE20231376A1 (es) Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos
CO2023002034A2 (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
CL2023001462A1 (es) Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza
CO2024001388A2 (es) Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2
CL2021000146A1 (es) Anticuerpos humanizados contra psma
MX2024014591A (es) Anticuerpo anti-bdca2 y uso del mismo
CL2023003047A1 (es) Anticuerpo anti componente del complemento 1s (c1s)
UY37082A (es) Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv
CO2021010887A2 (es) Anticuerpos anti-trem1 y métodos relacionados
CL2022002727A1 (es) Anticuerpo anti-cd47 y usos del mismo
MX2025012023A (es) Anticuerpos que se unen a multiples sarbecovirus
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
AR117072A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
CO2025006994A2 (es) Anticuerpos anti–cd137 y métodos de uso
UY39687A (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo
EA201790403A1 (ru) Антитела против lag3 и антигенсвязывающие фрагменты